Literature DB >> 7532099

Neither whole inactivated virus immunogen nor passive immunoglobulin transfer protects against SIVagm infection in the African green monkey natural host.

F Siegel1, R Kurth, S Norley.   

Abstract

Attempts to protect against infection with simian immunodeficiency virus (SIV)mac grown in rhesus peripheral blood mononuclear cells (PBMCs) using whole inactivated virus immunogen or passive transfer of antibody have so far universally failed. However, such experiments have succeeded in the closely related human immunodeficiency virus (HIV)-2/cynomolgus system. To determine whether the failure in the SIVmac system is typical of primate lentiviruses we performed vaccination and passive transfer experiments using SIVagm (genetically distinct from SIVmac and HIV-2) in the natural African green monkey (AGM) host. To maximize the chances of success, both immunogen and challenge material were prepared using the molecular SIVagm3 clone. Two AGMs were immunized four times with whole inactivated SIVagm3 in RIBI adjuvant and two received intravenously a high dose of immunoglobulin (Ig) purified from a mixture of plasma from AGM, either naturally infected or infected with the homologous SIVagm3 clone. All were challenged with 20 median minimum infective doses of the SIVagm3 grown in AGM PBMCs and previously titrated in AGMs. Despite a strong humoral immune response in all monkeys at the time of challenge, including measurable neutralizing and antibody-dependent cell-mediated cytotoxicity antibodies, none were protected from infection.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7532099     DOI: 10.1097/00042560-199503010-00001

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr Hum Retrovirol        ISSN: 1077-9450


  8 in total

1.  Live, attenuated simian immunodeficiency virus vaccines elicit potent resistance against a challenge with a human immunodeficiency virus type 1 chimeric virus.

Authors:  R Shibata; C Siemon; S C Czajak; R C Desrosiers; M A Martin
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

Review 2.  Antibody-dependent cellular cytotoxicity in HIV infection.

Authors:  Donald N Forthal; Andrés Finzi
Journal:  AIDS       Date:  2018-11-13       Impact factor: 4.177

3.  Vaccine effect using a live attenuated nef-deficient simian immunodeficiency virus of African green monkeys in the absence of detectable vaccine virus replication in vivo.

Authors:  B Beer; M Baier; J zur Megede; S Norley; R Kurth
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-15       Impact factor: 11.205

Review 4.  Evolutionarily conserved T-cell epitopes on FIV for designing an HIV/AIDS vaccine.

Authors:  J R Abbott; M P Sanou; J K Coleman; J K Yamamoto
Journal:  Vet Immunol Immunopathol       Date:  2011-06-12       Impact factor: 2.046

Review 5.  Immunodeficiency lentiviral infections in natural and non-natural hosts.

Authors:  Jason M Brenchley; Mirko Paiardini
Journal:  Blood       Date:  2011-04-19       Impact factor: 22.113

6.  Synergistic neutralization of simian-human immunodeficiency virus SHIV-vpu+ by triple and quadruple combinations of human monoclonal antibodies and high-titer anti-human immunodeficiency virus type 1 immunoglobulins.

Authors:  A Li; H Katinger; M R Posner; L Cavacini; S Zolla-Pazner; M K Gorny; J Sodroski; T C Chou; T W Baba; R M Ruprecht
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

7.  Effect of B-cell depletion on viral replication and clinical outcome of simian immunodeficiency virus infection in a natural host.

Authors:  Thaidra Gaufin; Melissa Pattison; Rajeev Gautam; Crystal Stoulig; Jason Dufour; Jeanne MacFarland; Daniel Mandell; Coty Tatum; Matthew H Marx; Ruy M Ribeiro; David Montefiori; Cristian Apetrei; Ivona Pandrea
Journal:  J Virol       Date:  2009-08-05       Impact factor: 5.103

8.  Engineered CD4- and CXCR4-using simian immunodeficiency virus from African green monkeys is neutralization sensitive and replicates in nonstimulated lymphocytes.

Authors:  Renate R König; Egbert Flory; Stefanie Steidl; Jeanette Neumann; Cheick Coulibaly; Edgar Holznagel; Silke Holzammer; Stephen Norley; Klaus Cichutek
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.